Vivatlac in Irritable Bowel Syndrome II (ViIBS2)

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Irritable Bowel Syndrome

In brief

Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients

Key facts

Study ID
NCT07235215
Run by
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
People needed
200
Starts
2025-11-21
Expected to finish
2027-12-01
Last updated by the study team
2025-12-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.